We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Advanced Melanoma

Journal Scan / Research · October 27, 2022

Nivolumab and Adoptive Cell Therapy With Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma

Clinical Cancer Research


Additional Info

Clinical Cancer Research
Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma
Clin. Cancer Res 2022 Oct 10;[EPub Ahead of Print], MS Hall, JE Mullinax, CA Cox, AM Hall, MS Beatty, J Blauvelt, P Innamarato, L Nagle, H Branthoover, D Wiener, B Schachner, AJ Martinez, AD Richards, CJ Rich, M Colón Colón, MJ Schell, JK Teer, NI Khushalani, JS Weber, JJ Mule, VK Sondak, S Pilon-Thomas, AA Sarnaik

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading